focus -WSS

focus

author：explore 2025-09-29 16:21:18 - browse：1

Jamy Ard (left) and Robert Lustig (right) on the 2023 STAT Breakthrough Summit stage -- coverage from STAT — Obesity experts Jamy Ard (left) and Robert Lustig speak at a panel during the 2023 STAT Breakthrough Summit. Sarah Gonzalez for STAT

Amid rising demand for drugs like Wegovy, Ozempic, and Mounjaro that can lead to significant weight loss, some obesity experts are concerned about the drugs’ costs — both to patients’ finances and to their health.

Speaking at a panel on new obesity treatments at the STAT Breakthrough Summit in San Francisco on Thursday, one expert cited a large clinical trial for Wegovy that showed that about 40% of the weight participants lost was lean mass. Side effects like nausea, vomiting, and a possible link to rare cases of pancreatitis also still plague this newest class of drugs, which imitate the effects of a hormone called glucagon-like peptide 1 (GLP) that helps people feel full.

“That’s what starvation does. You lose equal amounts of muscle and fat,” said Robert Lustig, emeritus professor of pediatrics at the University of California, San Francisco. “If you’re a person 60 years old or over and you’re losing muscle, your risk of dying just went up exponentially. So we may be … robbing Peter to pay Paul.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： FDA approves potent Eli Lilly obesity drug, Zepbound

focus

WSS

NIH study of ME/CFS points to clear biological hallmarks

The Sacklers, horror, and ‘The Fall of the House of Usher’

In utero gene editing: an explainer

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

FDA approves Recor Medical high blood pressure device

focus

focus

focus

Heart attack and stroke risk calculators need revising

New documents shed light on MD Anderson Cancer Institute feud

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6 phony surgeries that take placebo to the extreme

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Peter Hotez and the public health issue of online harassment

A clever new way to fix Medicaid and graduate medical education

Virginia high school admissions case could be legal follow

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

focus

Medicare will require more price transparency from hospitals

PBM reform efforts get punted in Congress

Ed Silverman on new gene therapies, biosimilars, coffee, and more

FDA approves potent Eli Lilly obesity drug, Zepbound

Medicare inequities exacerbate Puerto Rico’s health disparities

6 phony surgeries that take placebo to the extreme

focus

hotspot

leisure time

focus